Bitopertin – a Glycine Transporter Type I Inhibitor in Development

Roche is developing a synthetic glycine transporter type 1 (GlyT1) inhibitor that goes by the names RG1678 or Bitopertin.  If this molecule is approved as a medication it may help provide an option for individuals with schizophrenia who have already tried the natural GlyT1 inhibitor Sarcosine, or who are simply more comfortable with medication.

Understanding the role of NMDA Receptor Dysfunction in the Negative and Cognitive Symptoms of schizophrenia is not easy.  This site, from Genentech and Roche, appears to be a part of the education and marketing push behind Bitopertin or RG1678, but it may contain some useful information for patients and their families.  It does help explain the workings of the NMDA Receptor and the relationship between the neurotransmitters Glutamate and Glycine.

Links:    Genentech / Roche – NMDA and Schizophrenia

Roche’s press release for this medication.

Abstracts for recent research and development  – HERE and HERE.

Bitopertin or RG1678 is also mentioned in the comprehensive review of Glycine Transporter Type I Inhibitors – A Comprehensive Review from Hashimoto (PDF).

 

Posted in Uncategorized | Leave a comment

About This Site

Research into molecular medicine is discovering non-medication based treatments for many health disorders, and  schizophrenia is no different.  Our understanding of nutrient-based treatment options in schizophrenia is growing quickly.

SchizophreniaOptions is dedicated to exploring these options and raising awareness of natural and off-label treatments in this difficult condition. While there is a specific focus on Negative and Cognitive Symptoms, other issues are discussed as well.

This site started as a location for an archived presentation given to the National Alliance for Mental Illness (NAMI-LA) in May 2012.  It provides greater explanation of the importance of supporting NMDA receptor function in schizophrenia, as well as details regarding the research outcomes with NAC and Sarcosine in published studies.

Posted in Test | Leave a comment